Housey Pharma has entered into license agreements of its core-enabling technologies for new-drug discovery with the world’s two largest research-based pharmaceutical companies, F. Hoffman-La Roche (“Roche”) and the Janssen Research & Development subsidiary of Johnson & Johnson (“J&J”). This highly promising area of research in medicine may lead to a host of novel treatments for diseases such as drug-resistant cancers, diabetes, cardiovascular disease, CNS disorders such as dementia, and many other disease states for which current technologies were lacking.
Both Roche, based in Basel, Switzerland, and J&J’s Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to gain access to its core-enabling technology for new-drug discovery and development. Both Roche and J&J have annual Research and Development spending in excess of US $10 billion.
“Breakthroughs in the discovery and development of new medicines are enabled through the use of this advanced technology platform,” said Dr. Gerard Housey, M.D., Ph.D., President and CEO of Housey Pharma. “We look forward to seeing innovative new medicines that benefit people around the world brought forth by our scientific colleagues at Roche and J&J. These companies have been at the forefront of innovations in medicine ranging from new treatments in oncology to COVID-19 vaccines.”
